EICHOR
● Recruiting
NKG2D-CAR-NK92 Cells Immunotherapy for Solid Tumors
Condition: Relapsed/Refractory Solid Tumors · Sponsor: Henan Medical University
About this study
The purpose of this clinical investigation is to evaluate the safety and effects of NKG2D-CAR-NK92 infusions in the treatment of relapsed/refractory solid tumors.
This description comes directly from the study's public registry record.
Talk to the study team
Wuling Zhu · 008603733029089 · wulingzhu@xxmu.edu.cn
Always discuss trial participation with your own doctor first.
Locations (1)
| The first Affiliated Hospital of Xinxiang Medical University | Xinxiang, Henan, China | Recruiting |
Follow this study
Save your interest here for when the public record changes — results posted, or the study's status changes. Email alerts for this study aren't switched on yet.
We keep this only about this public record, and never email you without alerts being switched on. Want it removed at any time? Email hello@eichor.com. Never medical advice. By subscribing you agree to our Terms of Use and Privacy Policy.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT05528341